Home / Biosimilars / General / Biosimilars approved in the US
Biosimilars approved in the US Posted 14/08/2015

Last update: 5 March 2021 In the US, a legal framework for approving biosimilars was established in 2009, via the Biologics Price Competition and Innovation Act of 2009 (BPCI Act).
The BPCI Act is part of the healthcare reform legislation, which was signed into law on 23 March 2010 by President Barack Obama. The BPCI Act establishes an abbreviated approval pathway for biological products that are demonstrated to be ‘highly similar’ (biosimilar) to, or ‘interchangeable’ with, a US Food and Drug Administration (FDA)-licensed biological product. FDA is still in the process of developing guidelines regarding these types of products and has issued several guidance documents on the subject [1]. Zarxio (filgrastim-sndz) was the first product approved in the US as a biosimilar in 2015 [2]. To date, FDA has approved 29 biosimilars within the product classes of: 1) anti-tumour necrosis factor-alpha (TNF-α); 2) monoclonal antibodies; and 3) granulocyte colony-stimulating factor, plus five follow-on biologicals in the product classes of insulin (Admelog, Basaglar, Lusduna and Semglee) and teriparatide (PF708), for use in the US, see Table 1. The approval for one insulin glargine and teriparatide follow-on biological (PF708) are tentative pending patent litigation. Table 1: FDA approved biosimilars and follow-on biologicals* Product name Active substance Therapeutic area Authorization date Manufacturer/ Company name Abrilada (adalimumab-afzb) adalimumab
Ankylosing spondylitis 15 Nov 2019 Pfizer Admelog# insulin lispro Diabetes 11 Dec 2017 Sanofi Amjevita (adalimumab-atto) adalimumab
Ankylosing spondylitis 23 Sep 2016 Amgen Avsola (infliximab-axxq) infliximab
Ankylosing spondylitis 6 Dec 2019 Amgen Basaglar# insulin glargine Diabetes 16 Dec 2015
Eli Lilly/ Cyltezo (adalimumab-adbm) adalimumab
Ankylosing spondylitis 25 Aug 2017 Boehringer Ingelheim Erelzi (etanercept-szzs) etanercept
Axial spondyloarthritis 30 Aug 2016 Sandoz Eticovo (etanercept-ykro) etanercept
Axial spondyloarthritis 25 Apr 2019 Samsung Bioepis Fulphila (pegfilgrastim-jmdb) pegfilgrastim Febrile neutropenia 4 Jun 2018 Biocon/Mylan Hadlima (adalimumab-bwwd) adalimumab
Ankylosing spondylitis 23 Jul 2019 Samsung Bioepis Herzuma (trastuzumab-pkrb) trastuzumab Breast cancer 14 Dec 2018 Celltrion/Teva Pharmaceutical Industries Hulio (adalimumab-fkjp) adalimumab
Ankylosing spondylitis 6 Jul 2020 Mylan Hyrimoz (adalimumab-adaz) adalimumab
Ankylosing spondylitis 30 Oct 2018 Sandoz
Inflectra infliximab
Ankylosing spondylitis 5 Apr 2016 Pfizer (Hospira) Ixifi (infliximab-qbtx) infliximab
Ankylosing spondylitis 13 Dec 2017 Pfizer Kanjinti (trastuzumab-anns) trastuzumab
HER2 breast cancer 13 Jun 2019 Amgen Lusduna# (tentative approval) insulin glargine Diabetes 22 Jul 2018 Merck Sharpe Dohme Mvasi (bevacizumab-awwb) bevacizumab
NSCLC 14 Sep 2017 Amgen/Allergan Nivestym (filgrastim-aafi) filgrastim
Autologous peripheral blood progenitor cell collection and therapy 20 Jul 2018 Pfizer (Hospira) Nyvepria (pegfilgrastim-apgf) pegfilgrastim Febrile neutropenia 10 Jun 2020 Pfizer (Hospira) Ogivri (trastuzumab-dkst) trastuzumab
HER2 breast cancer 1 Dec 2017 Biocon/Mylan Ontruzant (trastuzumab-dttb) trastuzumab
HER2 breast cancer 18 Jan 2019 Samsung Bioepis/Merck PF708# (tentative approval) teriparatide Osteoporosis 7 Oct 2019 Pfenex Renflexis (infliximab-abda) infliximab
Ankylosing spondylitis 21 Apr 2017 Samsung Bioepis/Merck Retacrit (epoetin alfa-epbx) epoetin alfa
Anaemia (chronic kidney disease, Zidovudine, chemotherapy) 15 May 2018 Pfizer (Hospira)
Riabni rituximab
Ankylosing spondylitis 17 Dec 2020 Amgen Ruxience (rituximab-pvvr) rituximab
Chronic lymphocytic leukemia 23 Jul 2019 Pfizer Semglee (MYL‑1501D)# insulin glargine Diabetes 11 Jun 2020 Mylan/Biocon Trazimera (trastuzumab-qyyp) trastuzumab
HER2 breast cancer 11 Mar 2019 Pfizer Truxima (rituximab-abbs) rituximab Non-Hodgkin lymphoma 28 Nov 2018 Celltrion/Teva Pharmaceutical Industries Udenyca (pegfilgrastim-cbqv) pegfilgrastim Febrile neutropenia 2 Nov 2018 Coherus Biosciences
Zarxio filgrastim
Autologous peripheral blood progenitor cell collection and therapy 6 Mar 2015 Sandoz Ziextenzo (pegfilgrastim-bmez) pegfilgrastim Febrile neutropenia 4 Nov 2019 Sandoz Zirabev (bevacizumab-bvzr) bevacizumab
NSCLC 27 June 2019 Pfizer
*Data updated 5 March 2021 The landmark decision by FDA to approve its first biosimilar came in the wake of a unanimous vote two months earlier by FDA advisors who recommended approval of Zarxio [3]. Sandoz, the generics division of Novartis, already markets its biosimilar filgrastim product under the brand name Zarzio in more than 40 countries outside the US [4]. All the products approved so far have been approved as biosimilars, not as interchangeable products. According to the BPCI Act, only a biological that has been approved as interchangeable may be substituted for the reference product without the intervention of the healthcare provider who prescribed the reference product. FDA has designated placeholder non-proprietary names that include a 4-digit random suffix, for all of the biosimilars that it has approved to date. The agency issued final guidance on the naming of biologicals in January 2017 [5].
Related articles
References Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.
Crohn’s disease
Juvenile arthritis
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Crohn’s disease
Juvenile arthritis
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Crohn’s disease
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Boehringer Ingelheim
Crohn’s disease
Juvenile arthritis
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Polyarticular juvenile idiopathic arthritis
Psoriatic arthritis
Plaque psoriasis
Rheumatoid arthritis
Polyarticular juvenile idiopathic arthritis
Psoriatic arthritis
Plaque psoriasis
Rheumatoid arthritis
Crohn’s disease
Juvenile arthritis
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Crohn’s disease
Juvenile arthritis
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Crohn’s disease
Juvenile arthritis
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
(infliximab- dyyb)
Crohn’s disease
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Crohn’s disease
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
HER2 metastatic gastric or gastroesophageal junction adenocarcinoma
Colorectal neoplasms
Renal cell carcinoma
Ovarian neoplasms
Breast neoplasms
Bone marrow transplantation
Cancer
Myeloid leukaemia
Neutropenia
HER2 metastatic gastric or gastroesophageal junction adenocarcinoma
HER2 metastatic gastric or gastroesophageal junction adenocarcinoma
Crohn’s disease
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Reduction of allogeneic red blood cell transfusions
(rituximab-arrx)
Crohn’s disease
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Non-Hodgkin lymphoma
Granulomatosis with polyangiitis
HER2 metastatic gastric or gastroesophageal junction adenocarcinoma
(filgrastim-sndz)
Bone marrow transplantation
Cancer
Myeloid leukaemia
Neutropenia
Cervical cancer
Colorectal cancer
Renal cell carcinoma
Breast neoplasms
#Admelog, Basaglar, Lusduna and PF708 were approved via the FDA’s abbreviated 505(b)(2) pathway as follow-on products not as biosimilars. No insulin lispro or glargine products were licensed under the Public Health Service Act at the time of filing, so there was no ‘reference product’ for a proposed biosimilar product.
FDA: US Food and Drug Administration; NSCLC: Non-Small-Cell Lung Carcinoma; ODAC: Oncologic Drugs Advisory Committee
Biosimilars approved in Europe
1. GaBI Online - Generics and Biosimilars Initiative. US guidelines for biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 14]. Available from: www.gabionline.net/Guidelines/US-guidelines-for-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. FDA approves its first biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 14]. Available from: www.gabionline.net/Biosimilars/News/FDA-approves-its-first-biosimilar
3. GaBI Online - Generics and Biosimilars Initiative. FDA advisers recommend approval of filgrastim biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 14]. Available from: www.gabionline.net/Biosimilars/News/FDA-advisers-recommend-approval-of-filgrastim-biosimilar
4. GaBI Online - Generics and Biosimilars Initiative. FDA accepts biosimilar filgrastim application [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 14]. Available from: www.gabionline.net/Biosimilars/News/FDA-accepts-biosimilar-filgrastim-application
5. GaBI Online - Generics and Biosimilars Initiative. FDA issues final guidance on naming biologicals [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Feb 9]. Available from: www.gabionline.net/Guidelines/FDA-issues-final-guidance-on-naming-biologicals
Source: US FDA
Comments (3)
Response to ‘Biosimilars’ posted 18/03/2016 posted 05/10/2016 - by Louis B, GaBI Online Editorial Office
Dear Kauntay Parekh, thank you for your valid and interesting comment on this article. Thank you for sharing your thoughts on this subject. We would be delighted if you would consider submitting a short Commentary paper on this topic to GaBI Journal. Please feel free to reach us at editorial@gabi-journal.net for further information. Thank you again and we hope to hear from you soon. Best regards, Louis.Biosimilars posted 05/10/2016 - by Kauntay Parekh
Hi, Hemanth Kumar, 1. How many phase I, II, III trials are needed to be conducted for a Biosimilar in US and EU? Ans: In US and EU, biosimilar applicant has to discuss with drug regulatory authority to decide the clinical trial (CT) pathway for the particular product (For US FDA and for EU EMA). These regulatory authority devise the CT pathway based on the products similarity with reference biologic (Based on analytical data). Overall, the more similar the biosimilar product to reference product based on analytical data, the lesser CT will be required. 2. What is the trial duration for these trials (In general)? Ans: Trial duration varies from product to product but generally these trials get completed within 2-4 years. 3. How the development timelines and trial size differ for biosimilars from their reference biologic drugs? Ans: Unlike reference product sponsor, biosimilar applicant has to prove similarity, efficacy, safety and toxicity data comparable to reference biologic. Hence, the CT size required for biosimilar is smaller than the reference biologic.Biosimilars posted 02/09/2015 - by Hemanth Kumar G
Dear Sir/Madam, Thank you very much for your articles and news about Biosimilars and generics world at gabionline. I observed from one of your articles that it takes less than 2 years for completion of Biosimilar pivotal trials, I have a few queries regarding that. 1. How many phase I, II, III trials are needed to be conducted for a Biosimilar in US and EU? 2. What is the trial duration for these trials (In general) ? 3. How the development timelines and trial size differ for Biosimilars from their reference biologic drugs? I would be grateful if you can answer these queriesGenerics News Research General
- Dispensing branded drugs costs Medicare over a...Generics/Research | Posted 09/04/2021
- Technological approaches to drug repurposing fo...Generics/Research | Posted 02/04/2021
- EMA recommends approval of abiraterone and thio...Generics/News | Posted 02/04/2021
- Teva and Sandoz launch new genericsGenerics/News | Posted 26/03/2021
Biosimilars News Research General
- Adalimumab biosimilar FKB327 causes less pain t...Biosimilars/Research | Posted 09/04/2021
- Biosimilars regulation, clinical trials, approv...Biosimilars/Research | Posted 09/04/2021
- Biosimilars of ustekinumabBiosimilars/General | Posted 09/04/2021
- FDA accepts application for adalimumab biosimil...Biosimilars/News | Posted 09/04/2021